Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00131963
Status:
COMPLETED
Last Update Posted:
2016-07-25
First Post:
2005-08-16
Brief Title:
A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin ACyclophosphamide andor Weekly Paclitaxel
Sponsor:
Organization:
Duke University
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
False
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
SAMPLES_WITH_DNA
Bio Spec Description:
DNA will be extracted from blood samples taken at the first cycle of Doxorubicin andor Paclitaxel to analyze certain genes that may predict the severity of side-effects that may be experienced with chemotherapy
Enrollment Count:
94
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
| Name |
|---|
| Cohort |
Time Perspective List:
Clinical Trial Statuses
| Name |
|---|
| 711 |
Who Masked List: